Tisagenlecleucel

Therapeutic indications

Tisagenlecleucel is indicated for:

B-cell acute lymphoblastic leukaemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Tisagenlecleucel is indicated for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients 50 kg and below 0.2-5 x 10⁶ CAR-positive viable T cells/kg body weight and for patients >50 kg 0.1-2.5 x 10⁸ CAR-positive viable T cells

Relapsed or refractory diffuse large B-cell lymphoma

Population group: only adults (18 years old or older)

Tisagenlecleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.6-6 x 10⁸ CAR-positive viable T cells

Contraindications

Tisagenlecleucel is contraindicated in the following cases:

Effects on ability to drive and use machines

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.